Data Support Long-term Efficacy of Nuplazid for Psychosis

Data Support Long-term Efficacy of Nuplazid for Psychosis

296088

Data Support Long-term Efficacy of Nuplazid for Psychosis

Treatment with Nuplazid (pimavanserin) can ease symptoms of Parkinson’s disease psychosis (PDP) for up to 10 weeks, and is generally safe and well-tolerated, according to new clinical trial data. The findings were published in Parkinsonism and Related Disorders, in the study, “Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients.” Nuplazid, by Acadia Pharmaceuticals, is an oral medicine that was approved by the U.S. Food and Drug Administration (FDA) as a…

You must be logged in to read/download the full post.